Search Drug Information, Interactions, Images, Dosage & Side Effects

Risk of systemic adverse events similar after bevacizumab, ranibizumab, aflibercept 01 Mar 2021
The risk of acute myocardial infarction (MI), cardiovascular disease (CVD), major bleeding, or all-cause hospitalization is comparable following treatment with intravitreal bevacizumab, ranibizumab, and aflibercept during routine clinical practice, a retrospective cohort study has shown.

Polaprezinc plus PPI noninferior to rebamipide plus PPI in ESD-induced ulcers

01 Mar 2021

Novel tool predicts survival in brain metastasis patients

01 Mar 2021

Anastrozole withdrawal may reverse anastrozole-induced bone loss

01 Mar 2021

Air pollution reaches deep into kids’ DNA

01 Mar 2021

Spine bone mineral density gains greater with denosumab vs alendronate

01 Mar 2021

Coffee may guard against seizure‐related respiratory dysfunction

01 Mar 2021

Even at suboptimal uptake, PrEP effective at preventing HIV in teen MSM

28 Feb 2021

In vitro fertilization contributes to neoplasm risk in offspring

28 Feb 2021

BRAFV600 wild-type status tied to poorer survival in advanced melanoma

28 Feb 2021

Continuity of care eases medical expenses in chronic shoulder pain

28 Feb 2021

A Guide on Primary Immunodeficiency Disease and Allergies 05 Feb 2021;

Primary immunodeficiency disease (PIDD) and allergies are two groups of conditions related to the immune system. However, they are uniquely different in terms of symptoms and treatment.

Optimizing metastatic hormone-sensitive prostate cancer treatment in advanced prostate cancer

Assoc Prof. Darren Poon, Assoc Prof. Edmund Chiong, 14 Jan 2021

ALL treatment: Current settings, future goals

Roshini Claire Anthony, 08 Jan 2021

Spotlight on multidrug-resistant gram-negative infections: New developments for an old problem

Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021

Trezilent

Contents : Alpelisib

Indications/Uses : In combination w/ fulvestrant for postmenopausal women & men w/ hormone-receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after endocrine-based regimen.

Vizimpro

Contents : Dacomitinib

Indications/Uses : 1st-line treatment of patients w/ metastatic non-small cell lung cancer (NSCLC) w/ epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations.

Adacel

Contents : Per 0.5 mL Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, pertactin 3 mcg, fimbriae types 2 & 3 5 mcg

Indications/Uses : Active booster immunization for prevention of tetanus, diphtheria & pertussis (whooping cough) in persons ≥4 yr. Passive protection against pertussis in early infancy following maternal immunization during pregnancy. Concomitant w/ inactivated poliomyelitis vaccine as alternative for 5th dose of tetanus, diphtheria & acellular pertussis vaccine (DTaP) in childn 4-6 yr.

New Molecule

3 New

New Indication

5 New

New Brand

2 New

pill identifier

Shape

Form

Color 1

Color 2

Markings

Shape

Form

Color 1

Color 2

Search Drug Information, Images & Medical News | MIMS Malaysia

Trezilent

Vizimpro

Adacel